JP2017523223A5 - - Google Patents

Download PDF

Info

Publication number
JP2017523223A5
JP2017523223A5 JP2017506879A JP2017506879A JP2017523223A5 JP 2017523223 A5 JP2017523223 A5 JP 2017523223A5 JP 2017506879 A JP2017506879 A JP 2017506879A JP 2017506879 A JP2017506879 A JP 2017506879A JP 2017523223 A5 JP2017523223 A5 JP 2017523223A5
Authority
JP
Japan
Prior art keywords
amino
methyl
azabicyclo
thia
hept
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017506879A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017523223A (ja
JP6576433B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/043868 external-priority patent/WO2016022724A1/en
Publication of JP2017523223A publication Critical patent/JP2017523223A/ja
Publication of JP2017523223A5 publication Critical patent/JP2017523223A5/ja
Application granted granted Critical
Publication of JP6576433B2 publication Critical patent/JP6576433B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017506879A 2014-08-08 2015-08-05 β−セクレターゼ阻害剤としてのシクロプロピル縮合チアジン−2−アミン化合物及び使用方法 Active JP6576433B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462035269P 2014-08-08 2014-08-08
US62/035,269 2014-08-08
PCT/US2015/043868 WO2016022724A1 (en) 2014-08-08 2015-08-05 Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use

Publications (3)

Publication Number Publication Date
JP2017523223A JP2017523223A (ja) 2017-08-17
JP2017523223A5 true JP2017523223A5 (enExample) 2018-09-13
JP6576433B2 JP6576433B2 (ja) 2019-09-18

Family

ID=54150645

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017506879A Active JP6576433B2 (ja) 2014-08-08 2015-08-05 β−セクレターゼ阻害剤としてのシクロプロピル縮合チアジン−2−アミン化合物及び使用方法

Country Status (12)

Country Link
US (2) US9550762B2 (enExample)
EP (1) EP3177618A1 (enExample)
JP (1) JP6576433B2 (enExample)
CN (1) CN106795147B (enExample)
AR (1) AR101483A1 (enExample)
AU (1) AU2015301028B2 (enExample)
CA (1) CA2957544C (enExample)
JO (1) JO3569B1 (enExample)
MX (1) MX381482B (enExample)
TW (1) TWI614250B (enExample)
UY (1) UY36263A (enExample)
WO (1) WO2016022724A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6374889B2 (ja) 2013-03-08 2018-08-15 アムジエン・インコーポレーテツド β−セクレターゼ阻害剤としての過フッ素化シクロプロピル縮合1,3−オキサジン−2−アミン化合物、及び使用方法
US9550762B2 (en) 2014-08-08 2017-01-24 Amgen, Inc. Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
WO2017024180A1 (en) 2015-08-06 2017-02-09 Amgen Inc. Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
EP3555084B1 (en) 2016-12-15 2022-03-16 Amgen Inc. Thiazine derivatives as beta-secretase inhibitors and methods of use
EP3555085B1 (en) * 2016-12-15 2020-12-02 Amgen Inc. Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use
CA3047286A1 (en) 2016-12-15 2018-06-21 Amgen Inc. Oxazine derivatives as beta-secretase inhibitors and methods of use
EP3555106B1 (en) 2016-12-15 2022-03-09 Amgen Inc. Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use
MX387729B (es) 2016-12-15 2025-03-18 Amgen Inc Derivados de dióxido de 1,4-tiazina y dióxido 1,2,4-tiadiazina como inhibidores de beta-secretasa y métodos de uso.
WO2018224455A1 (en) 2017-06-07 2018-12-13 Basf Se Substituted cyclopropyl derivatives
CN113087669B (zh) * 2019-12-23 2023-11-17 南京药石科技股份有限公司 一种4-氰基-5-溴嘧啶的制备方法
CN115684413A (zh) * 2022-11-01 2023-02-03 重庆市涪陵食品药品检验所 一种硫酸羟氯喹中硫酸二甲酯和硫酸二乙酯的检测方法

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441870A (en) 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
SI9300303A (en) 1993-06-08 1994-12-31 Krka Tovarna Zdravil Process for isolation of hypolipemic effective substance
JPH11507538A (ja) 1995-06-07 1999-07-06 アテナ ニューロサイエンシズ インコーポレイティド β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ
US20040234976A1 (en) 1998-09-24 2004-11-25 Gurney Mark E. Alzheimer's disease secretase, app substrates therefor, and uses therefor
KR100768381B1 (ko) 1998-09-24 2007-10-18 파마시아 앤드 업존 캄파니 엘엘씨 알츠하이머병 세크레타제
MY148233A (en) 2003-12-15 2013-03-29 Merck Sharp & Dohme Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US20090264415A2 (en) 2004-12-30 2009-10-22 Steven De Jonghe Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment
ES2476027T3 (es) 2005-10-25 2014-07-11 Shionogi & Co., Ltd. Derivados de aminodihidrotriazina
WO2008133273A1 (ja) 2007-04-24 2008-11-06 Shionogi & Co., Ltd. アルツハイマー症治療用医薬組成物
KR20100017255A (ko) * 2007-04-24 2010-02-16 시오노기 앤드 컴파니, 리미티드 환식기로 치환된 아미노다이하이드로싸이아진 유도체
AP2010005167A0 (en) 2007-08-01 2010-02-28 Pfizer Pyrazole compounds and their use as RAF inhibitors
HRP20151030T1 (hr) 2008-01-18 2015-11-06 Eisai R&D Management Co., Ltd. Kondenzirani derivat aminodihidrotiazina
TWI431004B (zh) 2008-05-02 2014-03-21 Lilly Co Eli Bace抑制劑
MX2010013256A (es) 2008-06-13 2010-12-21 Shionogi & Co Derivado heterociclico que contiene azufre que tiene actividad inhibitoria de beta-secretasa.
WO2010013302A1 (ja) 2008-07-28 2010-02-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 スピロアミノジヒドロチアジン誘導体
AU2009277485B2 (en) 2008-07-28 2013-05-02 Eisai R&D Management Co., Ltd. Spiroaminodihydrothiazine derivatives
US8461160B2 (en) 2009-05-08 2013-06-11 Hoffmann-La Roche, Inc. Dihydropyrimidinones
AR077277A1 (es) 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
GB0912778D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
US8188079B2 (en) 2009-08-19 2012-05-29 Hoffman-La Roche Inc. 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines
US20110065695A1 (en) 2009-09-11 2011-03-17 Jeremy Beauchamp Use of aminodihydrothiazines for the treatment or prevention of diabetes
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
EP2500344A4 (en) 2009-11-13 2013-05-01 Shionogi & Co AMINOTHIAZIN OR AMINOOXAZINE DERIVATIVES WITH AN AMINO TERMINATION
JPWO2011070781A1 (ja) 2009-12-09 2013-04-22 塩野義製薬株式会社 置換アミノチアジン誘導体
WO2011071057A1 (ja) 2009-12-09 2011-06-16 塩野義製薬株式会社 含硫黄複素環誘導体を含有するアルツハイマー症の治療用または予防用医薬組成物
US7964594B1 (en) 2009-12-10 2011-06-21 Hoffmann-La Roche Inc. Amino oxazine derivatives
UA103272C2 (uk) 2009-12-11 2013-09-25 Ф. Хоффманн-Ля Рош Аг 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
JPWO2011071135A1 (ja) 2009-12-11 2013-04-22 塩野義製薬株式会社 オキサジン誘導体
EP2511269A4 (en) 2009-12-11 2013-04-24 Shionogi & Co FUSED HETEROCYCLIC COMPOUND HAVING AN AMINO GROUP
CN103108927B (zh) 2010-09-24 2015-12-16 可乐丽股份有限公司 糊料和将其涂膜作为电解质膜、电极膜的高分子换能器
CA2824097A1 (en) 2011-01-12 2012-07-19 Novartis Ag Oxazine derivatives and their use in the treatment of neurological disorders
JP2014505689A (ja) * 2011-01-13 2014-03-06 ノバルティス アーゲー 代謝障害の処置用bace−2阻害剤
US8404680B2 (en) 2011-02-08 2013-03-26 Hoffmann-La Roche Inc. N-[3-(5-amino-3,3a,7,7a-tetrahydro-1H-2,4-dioxa-6-aza-inden-7-yl)-phenyl]-amides as BACE1 and/or BACE2 inhibitors
EP2694489B1 (en) 2011-04-07 2017-09-06 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US8754075B2 (en) 2011-04-11 2014-06-17 Hoffmann-La Roche Inc. 1,3-oxazines as BACE1 and/or BACE2 inhibitors
CN103649082A (zh) * 2011-04-26 2014-03-19 盐野义制药株式会社 吡啶衍生物和含有该吡啶衍生物的bace1抑制剂
WO2012147763A1 (ja) 2011-04-26 2012-11-01 塩野義製薬株式会社 オキサジン誘導体およびそれを含有するbace1阻害剤
EP2517898A1 (de) 2011-04-29 2012-10-31 Lanxess Deutschland GmbH Kieselsäurehaltige Kautschukmischungen mit schwefelhaltigen Additiven
US8785436B2 (en) 2011-05-16 2014-07-22 Hoffmann-La Roche Inc. 1,3-oxazines as BACE 1 and/or BACE2 inhibitors
US8604024B2 (en) 2011-05-24 2013-12-10 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
US8598161B2 (en) 2011-05-24 2013-12-03 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
US9079919B2 (en) 2011-05-27 2015-07-14 Hoffmann-La Roche Inc. Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as BACE1 and/or BACE2 inhibitors
JP2012250933A (ja) 2011-06-03 2012-12-20 Shionogi & Co Ltd オキサジン誘導体を含有するアルツハイマー症治療用または予防用医薬組成物
AR086653A1 (es) 2011-06-03 2014-01-15 Bristol Myers Squibb Co COMPUESTOS PARA LA REDUCCION DE PRODUCCION DE b-AMILOIDE
WO2012168164A1 (en) 2011-06-07 2012-12-13 F. Hoffmann-La Roche Ag Halogen-alkyl-1,3 oxazines as bace1 and/or bace2 inhibitors
RU2599256C2 (ru) 2011-06-07 2016-10-10 Ф. Хоффманн-Ля Рош Аг [1,3]оксазины
US8927535B2 (en) * 2011-07-06 2015-01-06 Hoffman-La Roche Inc. Cyclopropyl-fused-1,3-thiazepines as BACE1 and/or BACE2 inhibitors
BR112014004181A2 (pt) 2011-08-22 2017-06-13 Merck Sharp & Dohme composto, composição farmacêutica, e, método de tratamento, prevenção, e / ou retardo do início de uma doença ou patologia
UY34278A (es) 2011-08-25 2013-04-05 Novartis Ag Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
WO2013030713A1 (en) 2011-08-31 2013-03-07 Pfizer Inc. Hexahydropyrano [3,4-d][1,3] thiazin-2-amine compounds
US20130073953A1 (en) 2011-09-21 2013-03-21 Timothy Onyenobi News headline screenshot viewing system
WO2013054291A1 (en) 2011-10-13 2013-04-18 Novartis Ag Novel oxazine derivatives and their use in the treatment of disease
WO2013061962A1 (ja) 2011-10-24 2013-05-02 武田薬品工業株式会社 二環性化合物
NZ625684A (en) 2012-01-26 2016-02-26 Hoffmann La Roche Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines
WO2013142613A1 (en) 2012-03-20 2013-09-26 Elan Pharmaceuticals, Inc. Spirocyclic dihydro-thiazine and dihydro-oxazine bace inhibitors, and compositions and uses thereof
DE102012005803A1 (de) 2012-03-21 2013-09-26 Wacker Neuson Produktion GmbH & Co. KG Bohr-und/oder Schlaghammer mit belastungsabhängiger Anpassung der Schlagzahl
WO2013164730A1 (en) 2012-05-04 2013-11-07 Pfizer Inc. Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin- 2 -amine compounds as inhibitors of app, bace1 and bace 2.
WO2013182638A1 (en) 2012-06-08 2013-12-12 H. Lundbeck A/S 2 -aminothiazinylheteroaryls as bace1 inhibitors for the treatment alzheimer's disease
CN104470915B (zh) 2012-06-26 2019-07-26 霍夫曼-拉罗奇有限公司 作为bace1抑制剂的二氟-六氢-环戊二烯并噁嗪基类和二氟-六氢-苯并噁嗪基类
GB201212871D0 (en) 2012-07-20 2012-09-05 Eisai Ltd Novel compounds
JP2015529239A (ja) 2012-09-20 2015-10-05 ファイザー・インク アルキル置換ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物
WO2014059185A1 (en) * 2012-10-12 2014-04-17 Amgen Inc. Amino - dihydrothiazine and amino - dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use
EP2908825B1 (en) 2012-10-17 2018-04-18 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2014062553A1 (en) 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP2912035A4 (en) 2012-10-24 2016-06-15 Shionogi & Co DERIVATIVES OF DIHYDROOXAZINE OR OXAZEPINE HAVING BACE1 INHIBITING ACTIVITY
US9328124B2 (en) 2012-10-26 2016-05-03 Eli Lilly And Company BACE inhibitors
US9447085B2 (en) 2012-12-14 2016-09-20 Merck Sharp & Dohme Corp. Iminothiadiazine dioxides containing a thioamide, amidine, or amide oxime group as BACE inhibitors, compositions, and their use
WO2014098831A1 (en) 2012-12-19 2014-06-26 Bristol-Myers Squibb Company 4,6-diarylaminothiazines as bace1 inhibitors and their use for the reduction of beta-amyloid production
CA2893333C (en) 2012-12-19 2017-10-24 Pfizer Inc. Carbocyclic-and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
CN104870000A (zh) 2012-12-20 2015-08-26 默沙东公司 作为bace抑制剂的c5,c6氧杂环稠合的亚胺基噻嗪二氧化物化合物,组合物及其用途
EP2934534B1 (en) 2012-12-21 2017-12-13 Merck Sharp & Dohme Corp. C5-spiro iminothiadiazine dioxides as bace inhibitors
MX2015008957A (es) 2013-01-22 2015-09-29 Siena Biotech Spa Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1).
AU2014223334C1 (en) 2013-03-01 2018-10-18 Amgen Inc. Perfluorinated 5,6-dihydro-4H-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
JP6374889B2 (ja) * 2013-03-08 2018-08-15 アムジエン・インコーポレーテツド β−セクレターゼ阻害剤としての過フッ素化シクロプロピル縮合1,3−オキサジン−2−アミン化合物、及び使用方法
US11447478B2 (en) 2013-04-11 2022-09-20 Hoffmann-La Roche Inc. BACE1 inhibitors
WO2014173917A1 (en) 2013-04-26 2014-10-30 F. Hoffmann-La Roche Ag Synthesis of bace1 inhibitors
TW201623295A (zh) 2014-04-11 2016-07-01 塩野義製藥股份有限公司 具有bace1抑制活性之二氫噻及二氫衍生物
WO2016001266A1 (en) 2014-07-04 2016-01-07 F. Hoffmann-La Roche Ag Fluoro-[1,3]oxazines as bace1 inhibitors
US9550762B2 (en) 2014-08-08 2017-01-24 Amgen, Inc. Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use

Similar Documents

Publication Publication Date Title
JP2017523223A5 (enExample)
JP7664947B2 (ja) Il-17の調節因子としてのイミダゾリダジン
JP7576552B2 (ja) イミダゾ[1,2-a]ピリジニル誘導体及び疾患の処置におけるその使用
JP5595616B2 (ja) トロポミオシン関連キナーゼ阻害薬としてのピロロ[2,3−d]ピリミジン誘導体
ES2649144T3 (es) Compuestos heteroaromáticos y su uso como ligandos de dopamina D1
CN105339370B (zh) 用于治疗炎症性疾病的化合物和及其药物组合物
JP6576433B2 (ja) β−セクレターゼ阻害剤としてのシクロプロピル縮合チアジン−2−アミン化合物及び使用方法
AU2020348675B2 (en) Azole-fused pyridazin-3(2H)-one derivatives
JP2016511258A5 (enExample)
CN112334466A (zh) 化合物
ES2807785T3 (es) Compuestos de heteroarilamina bicíclicos como inhibidores de pi3k
EA034931B1 (ru) Индолкарбоксамидные соединения
CA2934137A1 (en) Novel carboxamides, method for the production thereof, pharmaceutical preparations comprising them, and use thereof for producing medicaments
JP2013533868A (ja) タンパク質チロシンキナーゼ阻害剤としての新規ホモピペラジン誘導体およびそれらの医薬使用
WO2016051193A1 (en) Compounds useful as csf1 modulators
CA3067944A1 (en) Bicyclic ketone compounds and methods of use thereof
JP6322275B2 (ja) ヤヌスキナーゼ阻害剤としてのn−(2−シアノヘテロシクリル)ピラゾロピリドン
JP2023546742A (ja) Lpa受容体活性に付随する症状を治療するための化合物および組成物
CN112689636B (zh) 新型杂原子芳香族酰胺衍生物以及含有其的药剂
TW202412783A (zh) 酪胺酸激酶2抑制劑及其用途
HK40046970A (en) Novel heteroaromatic amide derivative and medicine containing same
HK40117760A (zh) Rip1调节剂、其制备及用途
HK40046970B (zh) 新型杂原子芳香族酰胺衍生物以及含有其的药剂
RU2020120705A (ru) Гетероциклические соединения в качестве ингибиторов prmt5
HK40003047A (en) 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides